Synergistic cytokine effects as apremilast response predictors in patients with psoriasis - 06/09/18
![](/templates/common/images/mail.png)
This study was sponsored by Celgene Corporation. |
|
Disclosure of potential conflict of interest: K. Nograles and P. H. Schafer are employees of and own stock in Celgene Corporation. J. G. Krueger has received grant/research support from AbbVie, Amgen, BMS, Boehringer Ingelheim, EMD Serono, Innovaderm, Kineta, LEO Pharma, Novan, Novartis, Paraxel, Pfizer, Regeneron, and Vitae Pharmaceuticals, and has received personal fees from AbbVie, Acros, Allergan, Aurigene, Biogen Idec, Boehringer Ingelheim, Eli Lilly, Escalier Biosciences, Janssen, Novartis, Pfizer, Roche, and Valeant. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 142 - N° 3
P. 1010 - septembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?